FDA News

Stay current with the latest press releases related to the FDA, offering insights into regulatory news, drug approvals, and policies that are influencing public health and pharmaceuticals. Learn about the key developments that are shaping the future of drug regulation.

Nov 20, 2026 at 6:25 PM

RxERP Outlines What the FDA’s Move to 12-Digit NDCs Means for Pharma Product Data

ST. GEORGE, Utah--(BUSINESS WIRE)--RxERP, the serialized enterprise resource planning platform purpose-built for the pharmaceutical supply chain, today released a 12-Digit NDC readiness overview and companion checklist to help pharmaceutical companies prepare their product records and workflows for the FDA’s new 12-digit NDC format. The resources build on RxERP’s support for 10-, 11-, and 12-digit representations of a product’s NDC within one product record, helping manufacturers, wholesalers,...
Nov 20, 2026 at 8:30 AM

Savara Informed That FDA Will Not Take Action on the Molgramostim BLA for Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP) by the PDUFA Date

YARDLEY, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), a clinical-stage biopharmaceutical company focused on rare respiratory diseases, today announced that the U.S. Food and Drug Administration (FDA) has communicated that it will not meet the Prescription Drug User Fee Act (PDUFA) target action date of November 22, 2026 for the Company’s molgramostim inhalation solution (molgramostim) Biologics License Application (BLA) for the treatment of autoimmune PAP. The review of the BLA is ongoing...
Nov 20, 2026 at 7:01 AM

Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases, today announced that, on November 16, 2026, the Compensation Committee of Precision’s Board of Directors approved the grant of inducement awards to new employees under the Precision BioSciences, Inc. 2021 Employment Inducement Incentive Award Plan (“Inducement Award...
Nov 20, 2026 at 7:00 AM

United Therapeutics Corporation Announces First Transplant in EXTEND Clinical Trial of UThymoKidney™ in Patients with End-Stage Renal Disease

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced the first clinical xenotransplant in its EXTEND study of the UThymoKidney™ in patients with ESRD. The transplant operation was performed at NYU Langone Health. The ongoing EXTEND study will evaluate the safety and efficacy of the UThymoKidney in ESRD patients who are not eligible for conventional allogeneic kidney transplantation or wh...
Nov 19, 2026 at 4:30 PM

Hyperfine to Present at the Piper Sandler 38th Annual Healthcare Conference on December 3

GUILFORD, Conn.--(BUSINESS WIRE)--Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared AI-powered portable MRI system for the brain—the Swoop® system—today announced that management will present at the Piper Sandler 38th Annual Healthcare Conference in New York on Thursday, December 3, 2026 at 9:10 a.m. Eastern Time. Management will also host in-person investor meetings at the conference. A live webcast, as well...
Nov 19, 2026 at 1:43 PM

a2z Radiology AI Expands Acute Care Suite with Third FDA-Cleared Device

BOSTON--(BUSINESS WIRE)--New FDA clearance brings a2z's abdomen-pelvis CT triage portfolio to 26 findings across three devices....
Nov 19, 2026 at 9:55 AM

The Science Behind Plan B: How Emergency Contraception Actually Works, According to OB/GYN Lauren Streicher, M.D.

NEW YORK--(BUSINESS WIRE)--THE SCIENCE BEHIND PLAN B: HOW EMERGENCY CONTRACEPTION ACTUALLY WORKS, ACCORDING TO OB/GYN LAUREN STREICHER, M.D....
Nov 19, 2026 at 8:00 AM

GE HealthCare’s Phase 2 Results Support Advancement of Investigational Manganese-Based MRI Contrast Agent Mangaciclanol Into Phase 3 of LUMINA Clinical Trial

CHALFONT ST. GILES, England--(BUSINESS WIRE)--GE HealthCare (Nasdaq: GEHC) today announced Phase 2 results support advancement into Phase 3 for its international, multicenter LUMINA trial of mangaciclanol, with a dose selection of 0.1mmol/kg. Mangaciclanol is an investigational manganese-based magnetic resonance imaging (MRI) contrast agent (MBCA). If approved, MBCAs could offer an alternative to – or even replace – gadolinium-based contrast agents (GBCAs), the current standard of care. This is...
Nov 19, 2026 at 7:30 AM

Zoetis Receives USDA License for Poulvac® Procerta® HVT-ND-ILT Vaccine for Chickens

PARSIPPANY, N.J.--(BUSINESS WIRE)--Zoetis Inc. (NYSE: ZTS) today announced that the U.S. Department of Agriculture (USDA) has licensed Poulvac® Procerta® HVT-ND-ILT, a vector vaccine for chickens. The license marks an important milestone in Zoetis’ continued investment and industry leadership in poultry health, disease protection, and innovation. Poulvac Procerta HVT-ND-ILT brings three disease targets together in one vaccine and expands the tools available to poultry veterinarians and producer...
Nov 19, 2026 at 7:00 AM

Alnylam Collaborator Regeneron Secures FDA Approval of Livsayis™ (cemdisiran), the Seventh FDA-Approved Therapeutic from Alnylam's RNAi Platform in Less Than Nine Years

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced that the U.S. Food and Drug Administration (FDA) has approved Livsayis™ (cemdisiran), an Alnylam-discovered RNAi therapeutic that was developed and will be commercialized by Regeneron, for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) antibody-positive. This marks the seventh Alnylam-discovered RNAi...
Turn Your News Into Headlines
Submit Your Release

Get Story Ideas Delivered to Your Inbox

Sign Up